© 2015 by Resdevco

Unit dose moisturizing Eye Drops for treating Conjunctivochalasis and Sjögren's syndrome

Resdevco's Dry eye drops have been clinically proven to treat Conjunctivochalasis. It is the only known non-surgical treatment of the disease that exists today, worldwide. The claim "Treatment for Conjunctivochalasis" is officially registered in Hungary and in the process of registration in other countries

Conjunctivochalasis represents one of the most common age-related eye diseases and is characterized by the presence of redundant folds of the conjunctiva that typically are detected between the eyeball and the eyelids. It is commonly found along the lower lid margin and   mechanically interferes with the normal distribution of tears giving rise to unstable tear film (dry eye) and delayed tear clearance (epiphora), hence frequent corneal inflammation

Resdevco's Dry eye drops have been clinically proven to treat Sjögren's syndrome. It is the only known treatment of the disease with zero side effects that exists today, worldwide. The claim "Treatment for Sjögren's syndrome" is officially registered in Holland and in the process of registration in other countries

Sjögren's syndrome is an autoimmune disease characterized by dryness of the mouth and eyes

Sjögren's syndrome with gland inflammation (resulting in dry eyes) that is not associated with another connective tissue disease is referred to as primary Sjögren's syndrome. Sjögren's syndrome that is also associated with a connective tissue disease, such as rheumatoid arthritis, systemic lupus erythematosus, or scleroderma, is referred to as secondary Sjögren's syndrome